Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.
from The Medical News http://ift.tt/1c3NBW5
from The Medical News http://ift.tt/1c3NBW5
No comments:
Post a Comment